The effect of hydrogen transported through gas pipelines on the performance of natural gas grid

The increasing production of electricity from renewable energy sources has been accompanied by growing interest in technologies allowing the storage of energy. One of the means allowing its storage is the Power-to-Gas technology thanks to which the excess power may be converted into another energy carrier such as hydrogen. One possibility is to blend the resulting hydrogen with natural gas and inject it into the natural gas grid. The paper discusses both the effect that hydrogen blend has on the performance of gas pipelines, and the main thermodynamic events occurring while the mixture of hydrogen and natural gas is transported

Gene therapy and the adeno associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: trials, future directions and safety considerations

Voretigene neparvovec-rzyl was recently approved for the treatment of Leber Congenital Amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size, and is highly compartmentalized, significantly reducing systemic spread. Adeno-associated virus (AAV), with its low pathogenicity, prolonged expression profile and ability to transduce multiple cell types, has become the leading gene therapy vector. Target diseases have moved beyond currently untreatable inherited dystrophies to common, partially treatable acquired conditions such as exudative AMD and glaucoma, but use of the technology in these conditions imposes added obligations for caution in vector design. This review discusses the current status of AAV gene therapy trials in genetic and acquired ocular diseases, and explores new scientific developments which could help ensure effective and safe use of the therapy in the future